Puretech Health Plc Stock Today
| PRTC Stock | USD 16.71 1.13 6.33% |
PerformanceVery Weak
| Odds Of DistressLow
|
PureTech Health is trading at 16.71 as of the 20th of March 2025, a 6.33 percent decrease since the beginning of the trading day. The stock's open price was 17.84. PureTech Health has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of November 2020 | Category Healthcare | Classification Health Care |
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company has 24.02 M outstanding shares of which 23.42 K shares are at this time shorted by private and institutional investors with about 16.81 trading days to cover. More on PureTech Health PLC
Moving against PureTech Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
PureTech Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CoFounder President | Eric Elenko | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsPureTech Health can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand PureTech Health's financial leverage. It provides some insight into what part of PureTech Health's total assets is financed by creditors.
| |||||
PureTech Health PLC (PRTC) is traded on NASDAQ Exchange in USA. It is located in 6 Tide Street, Boston, MA, United States, 02210 and employs 90 people. PureTech Health is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 428.38 M. PureTech Health PLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 24.02 M outstanding shares of which 23.42 K shares are at this time shorted by private and institutional investors with about 16.81 trading days to cover.
PureTech Health PLC currently holds about 368.03 M in cash with (105.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.84.
Check PureTech Health Probability Of Bankruptcy
Ownership AllocationPureTech Health owns a total of 24.02 Million outstanding shares. Roughly 98.44 pct. of PureTech Health outstanding shares are held by general public with 1.56 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check PureTech Ownership Details
PureTech Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Birch Hill Investment Advisors Llc | 2024-12-31 | 302 K | |
| Millennium Management Llc | 2024-12-31 | 45.3 K | |
| Pentwater Capital Management Lp | 2024-12-31 | 24.1 K | |
| Ubs Group Ag | 2024-12-31 | 1.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 100.0 | |
| Adar1 Capital Management Llc | 2024-12-31 | 0.0 | |
| Tower Research Capital Llc | 2024-09-30 | 0.0 |
PureTech Health Historical Income Statement
PureTech Stock Against Markets
PureTech Health Corporate Management
| Anita JD | Senior Property | Profile | |
| Lauren MBA | Chief Officer | Profile | |
| David Elmaleh | CoFounder Advisor | Profile | |
| Spencer Ball | Senior Resources | Profile | |
| III JD | General Secretary | Profile | |
| Joseph Bolen | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PureTech Health PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PureTech Health. If investors know PureTech will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PureTech Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.615 | Earnings Share (2.92) | Revenue Per Share | Quarterly Revenue Growth (0.91) | Return On Assets |
The market value of PureTech Health PLC is measured differently than its book value, which is the value of PureTech that is recorded on the company's balance sheet. Investors also form their own opinion of PureTech Health's value that differs from its market value or its book value, called intrinsic value, which is PureTech Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PureTech Health's market value can be influenced by many factors that don't directly affect PureTech Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PureTech Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if PureTech Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PureTech Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.